Cellectis Stock

Cellectis Liabilities

Delisted·Jun 19, 2026

The The Liabilities of Cellectis (ALCLS.PA) as of Aug 5, 2026 is 252.51 M USD. In the previous year, The Liabilities was 249.58 M USD — a change of 1.18% (higher).

Liabilities

252.51 MUSD

YoY

1.18%

Last updated:

In 2026, Cellectis's total liabilities amounted to 252.51 M USD, a 1.18% difference from the 249.58 M USD total liabilities in the previous year.

Access this data via the Eulerpool API

Cellectis Stock analysis

What does Cellectis do? Cellectis SA is an emerging biotechnology company focused on developing innovative therapies for cancer and other serious diseases. It was founded in 1999 by a French scientist named André Choulika and is headquartered in Paris, France. Cellectis' main business is the development of CAR-T cell therapies, which involve reprogramming immune cells to target specific types of cancer. This method specifically targets cancer cells while leaving healthy cells unaffected, offering a more precise and less invasive alternative to traditional cancer treatments. Cellectis' business model is centered around developing tailored cancer treatments for individual patients using its Cellectis System, a combination of genomic and cellular technologies. The company also has subsidiaries and joint ventures focusing on different segments of the biopharmaceutical market, such as Calyxt, which specializes in genetic modification of crops, and Ectycell, which focuses on developing cell therapies for rare blood diseases. Cellectis offers a range of products and services focused on cancer drug development, including cell therapies, genetic testing, clinical trials, and consulting services. Its products and services are tailored to the individual needs of patients and aim to revolutionize cancer treatment through advanced technology and innovative approaches. In summary, Cellectis is an innovative biotechnology company successfully focusing on developing tailored cancer therapies. With its wide range of products and services catering to patient needs, and with advancements in cancer therapy, Cellectis is well positioned to become a key player in the biopharmaceutical industry. Cellectis is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Cellectis's Liabilities

Cellectis's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Cellectis's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Cellectis's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Cellectis's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Cellectis’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Cellectis stock

The Liabilities of Cellectis is 252.51 M USD in 2026.

The Liabilities of Cellectis changed from 249.58 M USD to 252.51 M USD, representing a 1.18% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Cellectis since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Cellectis historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Cellectis

All Key Metrics — Cellectis